Research led by the Chiba Cancer Center Research Institute in Japan has discovered a surprising way cancer evades the immune ...

An injectable hydrogel platform shows promise in local immunotherapy for triple-negative breast cancer, enhancing treatment ...

Discover how a new study highlights the transformative potential of Th2 immunity in early cancer intervention.

After a Stage 4 cancer diagnosis and a prognosis of 16 months to live, Katie Doble didn’t know whether she should plan her ...

The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of ...

The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of cytotoxic T lymphocytes ...

The anti-correlation of PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells suggests the potential for combination therapy ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study. The experimental approach, which uses tiny capsules called small ...

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...

Molecular Partners' DARPin platform shows promise, but future funding is uncertain. Learn why MOLN stock could be a risky, ...